Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TLX · Nasdaq · United States · Pharmaceutical Preparations
In shortTelix Pharmaceuticals Ltd is loss-making, burns cash and carries moderate debt, with revenue growing (+55.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 3.7% | 29/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -0.9% | 16/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -1.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 2.9% | 19/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.43× | 52/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.98× | 57/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 5.13× | 0/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 0.73× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.88 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -5.3% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 3 | 58/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 3 | 67/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 2 | 100/100 |
| Revenue growth volatility | 0.3% | 100/100 |
| Operating margin volatility | 4.1% | 71/100 |
Weight in the score: 20%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 3 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 333 | 517 | 804 |
| Cost of revenue | 123 | 180 | 377 |
| Gross profit | 210 | 336 | 426 |
| Research & development | 85 | 128 | 171 |
| Operating income | 11 | 55 | 30 |
| Interest expense | 9.1 | 24 | 41 |
| Pre-tax income | 2.6 | 38 | (5.3) |
| Income tax | (1.6) | 4.2 | 1.9 |
| Net income | 4.2 | 34 | (7.1) |
| Diluted EPS | $0.01 | $0.10 | −$0.02 |
| Diluted shares (millions) | 324 | 345 | 338 |
0.88 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Feb 20, 2026